Drug Profile
Research programme: cannabinoid-based therapeutics - Tetra Bio-Pharma/Panag Pharma
Alternative Names: PPP-009Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Panag Pharma
- Developer Panag Pharma; Tetra Bio Pharma
- Class Analgesics; Anti-inflammatories; Eye disorder therapies
- Mechanism of Action Cannabinoid receptor CB2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Epidermolysis bullosa
- No development reported Complex regional pain syndromes; Inflammation; Neuropathic pain; Ocular inflammation; Ocular pain; Uveitis
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Uveitis in Canada
- 28 Jun 2022 No recent reports of development identified for preclinical development in Neuropathic-pain in Canada (Topical)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Ocular-inflammation in Canada (Ophthalmic)